Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27

The last day of trading of SpectraCure AB (publ) TO3 is Wednesday, November 27th,  2019.

Subscription of shares supported by the warrants in the TO3 program, implies that every two (2) warrants entitles the holder to subscribe for one (1) new share in SpectraCure at the subscription price of SEK 6.50.

If all warrants are fully exercised, the company cash position will increase by a total of approximately MSEK 37.1 MSEK after deduction of related issue costs.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope